Skip to main content
KALA logo

KALA · KALA BIO, Inc.

Track KALA — free
$2.71 -0.31 (-10.28%) At close · Nov 20
Market Cap
$1.74M
Shares
644,660
Volume · Nov 20 19.23K Avg daily vol (5 sessions) 17.3K

Price & Indicators

 

Key stats

Close
$2.71
Fri 20 Nov
Open
$3.02
Fri 20 Nov
Average volume, 5 days available
17K
shares a session
Short interest
13K
2.0% of shares · 1.8 days to cover
Day range
$2.65$3.17
Open $3.02 Close $2.71
Available closing range
$2.71$3.83
Close $2.71 29.4% under the high
Short volume, last session
49%
Last earnings
Aug 8, 2025
Latest filing
10-Q · Aug 19
Price history
Nov 2026 to Nov 2026

The closing range uses available history since Nov 16, 2026; less than a full year is stored.

Up next

call held Aug 11, 2022

Latest documents

2026
Nov 16
Current report 8-K Events of Nov 13
Nasdaq conditionally retains listing through February 23, 2027

Nasdaq granted KALA BIO, Inc. continued listing on The Nasdaq Capital Market, requiring a closing bid price of at least $1.00 per share from November 30, 2026 through February 23, 2027. The company had received a bid-price deficiency notice for July 16, 2026 through August 26, 2026.

Other events
2 source passages
On November 13, 2026, the Panel granted the Company’s request to continue its listing on Nasdaq subject to the following conditions: (i) the Company shall evidence a closing bid price of at least $1.00 per share for ten consecutive business days by November 30, 2026; (ii) the Company must maintain a closing bid price of at least $1.00 for each trading day after November 30, 2026 until February 23, 2027; and (iii) if the Company becomes non-compliant with any other Nasdaq listing rule prior to February 23, 2027, the Company will be allowed seven days to advise the Panel on the Company’s plan to cure the listing deficiency and the Panel shall determine whether to grant the Company an exception to cure the deficiency or delist the Company. On August 27, 2026, KALA BIO, Inc. (the “Company”) received a letter (the “Staff Determination Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Staff has determined that the closing bid price of the Company’s common stock, par value $0.001 per share (the “Common Stock”), has been below $1.00 per share for the previous 30 consecutive business days (from July 16, 2026 through August 26, 2026) and, as a result, the Company is not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(a)(2). Open the document at this passage
Nov 13
Late filing notice NT 10-Q
Quarterly filing delayed for liquidity analysis

KALA BIO, Inc. needs additional time to complete its analysis and disclosure regarding liquidity and capital resources for the quarter ended September 30, 2026, and expects to file no later than the fifth calendar day following the prescribed filing deadline.

2 source passages
KALA BIO, Inc. (the “Company”) will not, without unreasonable effort and expense, be able to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 (the “Form 10-Q”) within the prescribed time period because the Company requires additional time to complete its analysis and disclosure regarding its liquidity and capital resources. The Company anticipates that it will file the Form 10-Q no later than the fifth calendar day following the prescribed filing date. Open the document at this passage
Nov 12
Current report 8-K
1-for-30 reverse stock split effective November 13, 2026

KALA BIO will effect a 1-for-30 reverse stock split, reducing outstanding common shares from 19,339,786 to approximately 644,659; split-adjusted Nasdaq trading begins November 16, 2026 under KALA.

Change to shareholders' rights, Charter or bylaw amendment, or fiscal year change, Other events
4 source passages
KALA BIO, Inc. (NASDAQ: KALA) (“KALA BIO” or the “Company”), today announced that it intends to effect a reverse stock split of its common stock, par value $0.001 per share (the “common stock”) at a ratio of 1 post-split share for every 30 pre-split shares. The reverse stock split will become effective at 4:05 p.m. on Friday, November 13, 2026. The reverse stock split will reduce the number of shares of the Company’s common stock outstanding from 19,339,786 shares to approximately 644,659 shares. The Company’s common stock will continue to be traded on the Nasdaq Capital Market under the symbol KALA and will begin trading on a split-adjusted basis when the market opens on Monday, November 16, 2026. Open the document at this passage
Nov 9
Current report 8-K
Quarterly net loss falls approximately 90% year over year

KALA BIO, Inc. reported preliminary third-quarter 2026 net loss of approximately $0.8 million, down from $7.6 million, and approximately $7.0 million in cash, cash equivalents and short-term investments with no debt.

Financial results
4 source passages
KALA BIO, Inc. (Nasdaq: KALA) today announced preliminary unaudited financial results for the quarter ended September 30, 2026. Net loss of approximately $0.8 million for the third quarter of 2026, compared to $7.6 million for the third quarter of 2025. Cash, cash equivalents and short-term investments of approximately $7.0 million as of September 30, 2026, with no debt. We reduced our quarterly net loss by approximately 90% year over year and continue to develop the initiatives we have put in motion. Open the document at this passage
Nov 3
Current report 8-K
Reverse split approved within 1-for-2 and 1-for-300 bounds

KALA BIO, Inc. stockholders approved a reverse stock split at a ratio of not less than 1-for-2 and not greater than 1-for-300. The Board of Directors will determine the timing and publicly announce the selected ratio.

Shareholder vote results
2 source passages
KALA BIO, INC. The Company’s stockholders voted to approve an amendment to the Restated Certificate of Incorporation to effect a reverse stock split of the Common Stock at a ratio of not less than 1-for-2 and not greater than 1-for-300 at such time as the Company’s Board of Directors shall determine, in its sole discretion, and to be included in a public announcement. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$10.08M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$7.23M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-43.1%
Year over year · fewer shares
Price change (1Y)
—
Trailing year
Short interest
2.0%
Latest settlement · 1.8 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Sell Momentum Limited Sentiment Bullish Fundamentals Strong Quant / Vol Moderate
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Sell
50 / 200-day cross No cross
52-week position 0%
near low
Momentum
relative strength
Limited
Not enough data for a confident read.
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+7% holders QoQ · +5 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
1.98% of shares out · ▼ -29.0% MoM · 1.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
16 holders — mid 3-yr range
Squeeze score 41
elevated · 0–100
Fundamentals
Strong
EPS growth +67%
Y/Y
Free cash flow $-33.3M
Balance sheet $20.7M
net cash
Quant / Vol
risk profile
Moderate
Volatility 41%
annualized · 1-yr
Max drawdown −29%
past year

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
1 · 1 · 0
50 / 200-day cross
No cross Neutral
52-week position
0% Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+7% holders QoQ · +5 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
1.98% of shares out · ▼ -29.0% MoM · 1.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
16 holders — mid 3-yr range
Price context
position in its available closing range
Range low $3 Now $3 · 0% Range high $4

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
KALA
KALA BIO, Inc.
this stock
$1.74M — — — 2.0%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
16
% held
4.4%
Net QoQ
+5.3K sh
Top holder
VANGUARD CAPITAL MANAGEME…
Held Float
View
Held by Funds
Fund positions
9
View
Short & Settlement
Short Interest Falling
Shares short
12.8K
Days to cover
1.8d
Change
-5.2K sh
View
Short Volume
Short vol %
49%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
30.0K
Value
$5.4K
As of
Oct 29, 2026
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-27.0M
EPS diluted
$-4965.00
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 16, 2026
This year
30

Nasdaq granted KALA BIO, Inc. continued listing on The Nasdaq Capital Market, requiring a closing bid price of at least $1.00 per share from November 30, 2026 through February 23, 2027. The company had received a bid-price deficiency notice for July 16, 2026 through August 26, 2026.

View
Proposed Sales
Value
$3.8K
Shares
14.5K
Filed
Mar 17, 2026
View
Exempt Offerings
Offering
$1.8M
Filed
Mar 17, 2026
View
Earnings & Events
Webcasts
Last webcast
Aug 8, 2025
View
Investor Relations
Latest news
KALA BIO Announces Reverse Stock…
Published
Nov 12, 2026
View

Performance

5D 20D 120D MTD YTD
KALA — — — — —
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY — — — — —
Key facts CIK 1479419 CUSIP 483119301 13F (30d) 23 filings 19 filers Visit website Investor relations